Since collecting the exclusive U.S. rights and data on the drug from Pfizer in 2020, Asxome has been busy building on its two earlier studies of AXS-12 in narcolepsy. Now, with fresh phase 3 data ...

017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with narcolepsy. AXS-12 is an investigational highly selective potent norepinephrine reuptake ...

Find effective medications for 'Narcolepsy treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to manage ...

For years, Jazz Pharmaceuticals has dominated the market in treating narcolepsy with cataplexy. But increased competition is on the horizon. Classic treatment options ...

Narcolepsy is a nervous system disorder that involves your brain. You struggle to manage sleep patterns and stay awake. No matter how much rest you got the night before, an intense urge to sleep ...

Some volunteers who tried the narcolepsy treatment ... voice" before developing laryngeal dystonia Botox (botulinum toxin) injections are often used to treat LD but are ineffective for up to ...

Axsome Therapeutics (NASDAQ:AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with cataplexy has met its primary endpoint. The study showed AXS-12 was able to ...

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is ...

Some volunteers who tried the narcolepsy treatment ... Botox (botulinum toxin) injections are often used to treat LD but are ineffective for up to 40% of patients, the researchers, from the ...

The new research was done with rhesus monkeys and may have therapeutic implications for people who suffer from narcolepsy and ... orexin-A (either intravenous injection or nasal spray) immediately ...